Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently emerged
pathogenic human coronavirus that belongs to the sarbecovirus lineage of the genus …

SARS-CoV-2 Omicron variant has presented significant challenges to current antibodies
and vaccines. Herein, we systematically compared the efficacy of 50 human monoclonal …

Abstract Current SARS-CoV-2 Omicron subvariants impose a heavy burden on global health
systems by evading immunity from most developed neutralizing antibodies and vaccines …

SARS-CoV-2 Omicron subvariants have demonstrated extensive evasion from monoclonal
antibodies (mAbs) developed for clinical use, which raises an urgent need to develop new …

Emerging severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) variants,
especially the Omicron variant, have impaired the efficacy of existing vaccines and most …

Coronavirus disease-19 (COVID-19) emerged in December 2019 and quickly spread, giving
rise to a pandemic crisis. Therefore, it triggered tireless efforts to identify the mechanisms of …

There is an unmet need for monoclonal antibodies (mAbs) for prevention or as adjunctive
treatment of herpes simplex virus (HSV) disease. Most vaccine and mAb efforts focus on …

Omicron, as the emerging variant with enhanced vaccine tolerance, has sharply disrupted
most therapeutic antibodies. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV …

The respiratory system, especially the lung, is the key site of pathological injury induced by
SARS-CoV-2 infection. Given the low feasibility of targeted delivery of antibodies into the …